ATE535545T1 - Chimäre und humanisierte monoklonale antikörper gegen interleukin-13 - Google Patents

Chimäre und humanisierte monoklonale antikörper gegen interleukin-13

Info

Publication number
ATE535545T1
ATE535545T1 AT05757024T AT05757024T ATE535545T1 AT E535545 T1 ATE535545 T1 AT E535545T1 AT 05757024 T AT05757024 T AT 05757024T AT 05757024 T AT05757024 T AT 05757024T AT E535545 T1 ATE535545 T1 AT E535545T1
Authority
AT
Austria
Prior art keywords
chimeric
monoclonal antibodies
antibodies against
humanized monoclonal
against interleukin
Prior art date
Application number
AT05757024T
Other languages
English (en)
Inventor
Claire Ashman
Martin John Cassidy
Jonathan Henry Ellis
Trevor Anthony Kenneth Wattam
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35521159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE535545(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0414799.7A external-priority patent/GB0414799D0/en
Priority claimed from GB0423675A external-priority patent/GB0423675D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE535545T1 publication Critical patent/ATE535545T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT05757024T 2004-07-01 2005-06-30 Chimäre und humanisierte monoklonale antikörper gegen interleukin-13 ATE535545T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0414799.7A GB0414799D0 (en) 2004-07-01 2004-07-01 Immunoglobulins
GB0423675A GB0423675D0 (en) 2004-10-25 2004-10-25 Immunoglobulins
PCT/GB2005/002581 WO2006003407A2 (en) 2004-07-01 2005-06-30 Chimeric and humanised monoclonal antibodies against inteleukin- 13

Publications (1)

Publication Number Publication Date
ATE535545T1 true ATE535545T1 (de) 2011-12-15

Family

ID=35521159

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05757024T ATE535545T1 (de) 2004-07-01 2005-06-30 Chimäre und humanisierte monoklonale antikörper gegen interleukin-13

Country Status (26)

Country Link
US (2) US7807788B2 (de)
EP (2) EP1802658B1 (de)
JP (1) JP5102616B2 (de)
KR (1) KR20070034609A (de)
AR (1) AR049565A1 (de)
AT (1) ATE535545T1 (de)
AU (1) AU2005259025B2 (de)
BR (1) BRPI0512826A (de)
CA (1) CA2571799A1 (de)
CY (1) CY1112372T1 (de)
DK (1) DK1802658T3 (de)
ES (2) ES2456897T3 (de)
HR (1) HRP20120139T1 (de)
IL (1) IL180152A0 (de)
MA (1) MA28726B1 (de)
MX (1) MX2007000026A (de)
NO (1) NO20070189L (de)
NZ (1) NZ552063A (de)
PE (1) PE20060376A1 (de)
PL (1) PL1802658T3 (de)
PT (1) PT1802658E (de)
RU (1) RU2404192C2 (de)
SG (1) SG153878A1 (de)
SI (1) SI1802658T1 (de)
TW (1) TWI307630B (de)
WO (1) WO2006003407A2 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
MXPA06000258A (es) * 2003-07-15 2006-07-03 Cambridge Antibody Tech Moleculas de anticuerpo humano para interleucina-13.
ES2775204T3 (es) 2003-12-23 2020-07-24 Genentech Inc Nuevos anticuerpos anti IL13 y usos de los mismos
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
CA2587903A1 (en) 2004-11-17 2006-05-26 Amgen Fremont Inc. Fully human monoclonal antibodies to il-13
EP1877074B1 (de) * 2005-04-15 2013-03-27 The Government of the United States of America, as represented by the Secretary of Health and Human Services Behandlung und prävention von entzündlicher darmerkrankung mit il-13 und nkt-zellen
WO2007036745A2 (en) 2005-09-30 2007-04-05 Medimmune Limited Interleukin-13 antibody composition
JP5006330B2 (ja) 2005-10-21 2012-08-22 ノバルティス アーゲー Ｉｌ１３に対するヒト抗体および治療的使用
GB0600488D0 (en) * 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
AU2007209202A1 (en) * 2006-01-24 2007-08-02 Domantis Limited Ligands that bind IL-4 and/or IL-13
JP2010502224A (ja) 2006-09-08 2010-01-28 アボット・ラボラトリーズ インターロイキン１３結合タンパク質
CN101522716B (zh) * 2006-10-02 2013-03-20 瑞泽恩制药公司 抗人il-4受体的高亲和力人抗体
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
DE102008053503B4 (de) * 2008-10-28 2011-04-28 Justus-Liebig-Universität Giessen Immunologischer Test zum Nachweis von Autoantikörpern gegen testikuläre Antigene
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
TW201107345A (en) * 2009-05-28 2011-03-01 Glaxo Group Ltd Immunoglobulins
RU2603055C2 (ru) 2009-10-20 2016-11-20 Эббви Инк Выделение и очистка антител против il-13 с применением аффинной хроматографии с белком а
WO2011119925A2 (en) * 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers
WO2012083132A2 (en) 2010-12-16 2012-06-21 Genentech, Inc. Diagnosis and treatments relating to th2 inhibition
RU2690675C2 (ru) 2012-08-21 2019-06-05 Санофи Байотекнолоджи Способы лечения или предотвращения астмы посредством введения антагониста il-4r
TWI679019B (zh) * 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
ES2915378T3 (es) 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
NZ756750A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
CA2924873A1 (en) 2013-10-23 2015-04-30 Genentech, Inc. Methods of diagnosing and treating eosinophilic disorders
CN106170497A (zh) 2014-02-07 2016-11-30 免疫医疗有限责任公司 检测人类骨膜蛋白的新型测定
WO2015127405A2 (en) 2014-02-21 2015-08-27 Genentech, Inc. Anti-il-13/il-17 bispecific antibodies and uses thereof
WO2015130975A1 (en) 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
AU2015246037B2 (en) 2014-04-11 2018-04-12 Novartis Ag Methods of selectively treating asthma using IL-13 antagonists
MX2017006286A (es) 2014-11-14 2018-01-23 Sanofi Biotechnology Metodos para tratar sinusitis cronica con polipos nasales por administracion de un antagonista de il-4r.
JP2018511797A (ja) 2015-03-16 2018-04-26 ジェネンテック， インコーポレイテッド ＩＬ−１３の検出方法及び定量方法並びにＴｈ２関連疾患の診断及び治療における使用
ITUB20155097A1 (it) * 2015-11-05 2017-05-05 Biouniversa Srl Anticorpi umanizzati anti-BAG3
PL3448391T3 (pl) 2016-04-27 2024-09-16 AbbVie Manufacturing Management Unlimited Company Sposoby leczenia chorób, w których jest szkodliwa aktywność il-13, przy zastosowaniu przeciwciała anty-il-13
JP2019527535A (ja) * 2016-05-18 2019-10-03 上海開拓者生物医薬有限公司Ｓｈａｎｇｈａｉ Ｐｈａｒｍａｅｘｐｌｏｒｅｒ Ｃｏ．， Ｌｔｄ． Ｉｌ−１３抗体およびその製造方法と使用
EP4442323A3 (de) 2016-09-01 2025-01-01 Regeneron Pharmaceuticals, Inc. Verfahren zur prävention oder behandlung von allergien durch verabreichung eines il-4r-antagonisten
US10485844B2 (en) 2016-09-22 2019-11-26 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an IL-4R inhibitor
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
WO2018106931A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
WO2019028367A1 (en) 2017-08-04 2019-02-07 Regeneron Pharmaceuticals, Inc. METHODS OF TREATING ESOPHAGITIS WITH ACTIVE EOSINOPHILES
KR20250044796A (ko) 2017-10-30 2025-04-01 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
JP7418337B2 (ja) 2018-02-09 2024-01-19 ジェネンテック， インコーポレイテッド マスト細胞媒介性炎症性疾患の治療法及び診断法
MA52624A (fr) 2018-05-13 2021-03-24 Regeneron Pharma Méthodes de traitement de la dermatite atopique par administration d'un inhibiteur de l'il-4r
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN116726361A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
CA3120578A1 (en) * 2018-12-03 2020-06-11 Dermata Therapeutics, Llc Compositions for the treatment of conditions
EP3935085A1 (de) 2019-03-06 2022-01-12 Regeneron Pharmaceuticals, Inc. Il-4- und il-13-signalweginhibitoren zur erhöhung der wirksamkeit bei der behandlung von krebs
PH12021552123A1 (en) 2019-03-21 2022-08-22 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
JP7592064B2 (ja) 2019-07-16 2024-11-29 サノフィ・バイオテクノロジー Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
AU2020326713A1 (en) 2019-08-05 2022-02-17 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2023130010A1 (en) 2021-12-30 2023-07-06 Regeneron Pharmaceuticals, Inc. Methods for attenuating atopic march by administering an il-4/il-13 antagonist
EP4227321A1 (de) * 2022-02-10 2023-08-16 AVA Lifescience GmbH Antikörper gegen den b-zell rezeptor chronischer lymphatischer leukämie (cll) zur verwendung bei der behandlung von cll
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (de) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformationsvektoren für Hefe Yarrowia
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
SK285960B6 (sk) 1991-07-25 2007-12-06 Biogen Idec Inc. Rekombinantné protilátky na liečenie ľudí
EP0605522B1 (de) 1991-09-23 1999-06-23 Medical Research Council Methoden zur Herstellung humanisierter Antikörper
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
SK279958B6 (sk) 1992-04-02 1999-06-11 Smithkline Beecham Corporation Zlúčeniny s protialergickým a protizápalovým účink
JPH08500017A (ja) 1992-08-17 1996-01-09 ジェネンテク，インコーポレイテッド 二特異的免疫アドヘジン
CA2163032C (en) 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5889056A (en) 1994-06-15 1999-03-30 Glaxo Wellsome Inc. Enzyme inhibitors
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
DE19723722A1 (de) 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
SI1070056T1 (en) 1998-03-14 2004-12-31 Altana Pharma Ag Phthalazinone pde iii/iv inhibitors
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
EP1073464B1 (de) 1998-04-28 2004-10-06 Smithkline Beecham Corporation Monoklonale antikörper mit verringerter immunisierungsfähigkeit
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
US6468528B1 (en) * 1999-02-01 2002-10-22 Amgen Canada Inc. Materials and methods to inhibit Hodgkin and Reed Sternberg cell growth
AU4501800A (en) 1999-05-04 2000-11-17 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US6263209B1 (en) 1999-07-28 2001-07-17 Motorola, Inc. Method and apparatus in a wireless communication system for creating a learning function
CO5180649A1 (es) 1999-09-01 2002-07-30 Abbott Lab Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
IL155093A0 (en) 2000-09-29 2003-10-31 Glaxo Group Ltd Morpholin-acetamide derivatives for the treatment on inflammatory diseases
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
US6484903B2 (en) 2001-01-09 2002-11-26 Riverwood International Corporation Carton with an improved dispensing feature in combination with a unique handle
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
GB0105360D0 (en) 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
ATE365720T1 (de) 2001-03-08 2007-07-15 Glaxo Group Ltd Agonisten von beta-adrenorezeptoren
WO2002076933A1 (en) 2001-03-22 2002-10-03 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
BRPI0212455B8 (pt) 2001-09-14 2021-05-25 Glaxo Group Ltd composto derivado de fenetanolamina para o tratamento de doenças respiratórias, formulação farmacêutica, combinação, e, uso do mesmo
JP2005505802A (ja) * 2001-09-20 2005-02-24 パイオニア株式会社 発光素子駆動回路
JP2005519897A (ja) 2002-01-14 2005-07-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメチックス、その製造方法、それを含む医薬製剤及びその使用
JP4745609B2 (ja) 2002-01-22 2011-08-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア グルココルチコイドレセプターのための非ステロイド性リガンド、その組成物および使用
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
JP4432031B2 (ja) * 2002-03-22 2010-03-17 ズィナイス オペレーションズ ピーティーワイ．エルティーディー． インターロイキン１３受容体α１（ＩＬ−１３Ｒα１）に対するモノクローナル抗体
WO2003082787A1 (en) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EA008830B1 (ru) 2002-03-26 2007-08-31 Бёрингер Ингельхайм Фармасьютиклз, Инк. Миметики глюкокортикоидов, способы их получения, фармацевтические композиции и их применение
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
AU2003223497A1 (en) * 2002-04-05 2003-10-27 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
ATE496620T1 (de) 2002-04-11 2011-02-15 Merck Sharp & Dohme 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
JP2005525404A (ja) 2002-05-01 2005-08-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｈｉｖ感染およびａｉｄｓを処置するためにサイトカインアンタゴニストを使用する方法
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DK1521733T3 (da) 2002-07-08 2014-10-13 Pfizer Prod Inc Modulatorer af glucocorticoid receptoren
WO2004009016A2 (en) 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Compositions and methods involving nuclear hormone receptor site ii
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
AU2003251970A1 (en) 2002-07-18 2004-02-09 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
NZ555692A (en) * 2002-07-19 2009-02-28 Abbott Biotech Ltd Treatment of TNF alpha related disorders
CA2496175A1 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE60329193D1 (de) 2002-09-16 2009-10-22 Glaxo Group Ltd Pyrazolo(3,4-b)pyridinverbindungen und ihre verwendung als phosphodiesterasinhibitoren
CA2499150A1 (en) 2002-09-20 2004-04-01 Merck & Co., Inc. Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
US7790405B2 (en) * 2004-04-26 2010-09-07 Centocor, Inc. Solution phase biopanning method using engineered decoy proteins
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos

Also Published As

Publication number Publication date
AU2005259025B2 (en) 2012-01-19
EP2436697A1 (de) 2012-04-04
RU2007103826A (ru) 2008-08-10
AR049565A1 (es) 2006-08-16
BRPI0512826A (pt) 2008-04-08
EP1802658B1 (de) 2011-11-30
EP1802658A2 (de) 2007-07-04
HRP20120139T1 (hr) 2012-03-31
JP5102616B2 (ja) 2012-12-19
TWI307630B (en) 2009-03-21
NZ552063A (en) 2010-01-29
MA28726B1 (fr) 2007-07-02
RU2404192C2 (ru) 2010-11-20
JP2008511542A (ja) 2008-04-17
AU2005259025A1 (en) 2006-01-12
PL1802658T3 (pl) 2012-04-30
US20070258979A1 (en) 2007-11-08
PT1802658E (pt) 2012-03-06
PE20060376A1 (es) 2006-06-02
SG153878A1 (en) 2009-07-29
WO2006003407A3 (en) 2006-04-27
KR20070034609A (ko) 2007-03-28
TW200612985A (en) 2006-05-01
EP2436697B1 (de) 2014-03-05
CA2571799A1 (en) 2006-01-12
MX2007000026A (es) 2007-03-07
SI1802658T1 (sl) 2012-03-30
IL180152A0 (en) 2007-06-03
WO2006003407A2 (en) 2006-01-12
US7807788B2 (en) 2010-10-05
DK1802658T3 (da) 2012-03-12
US20110243928A1 (en) 2011-10-06
CY1112372T1 (el) 2015-12-09
ES2378173T3 (es) 2012-04-09
NO20070189L (no) 2007-03-29
ES2456897T3 (es) 2014-04-23

Similar Documents

Publication Publication Date Title
ATE535545T1 (de) Chimäre und humanisierte monoklonale antikörper gegen interleukin-13
IL272883A (en) Monoclonal antibodies and their uses
IL190502A0 (en) Anti-addl monoclonal antibody and use thereof
EP1717250A4 (de) Monoklonaler antikörper und dessen verwendung
IL176755A0 (en) M-csf-specific monoclonal antibody and uses thereof
IL187710A0 (en) Anti-trkb monoclonal antibodies and uses thereof
ATE501174T1 (de) Antikörper gegen madcam
CY2012019I1 (el) Ανθρωπινα μονοκλωνα αντισωματα εναντια στο cd20
IL196550A0 (en) Anti-il-6 monoclonal antibodies and uses thereof
ZA200706425B (en) Anti-interferon alpha monoclonal antibodies and methods for use
IL186659A0 (en) Il-31 monoclonal antibodies and methods of use
IL179102A0 (en) HUMANIZED Fc??RIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
IL179672A (en) Monoclonal antibodies against 3 cd human
HRP20220755T3 (hr) Anti-gm-csf antitijela i njihova uporaba
HRP20151252T1 (xx) Modificirani fab ulomci protutijela
ATE480564T1 (de) Monoklonaler anti-mensch-tenascin-antikörper
EP2077325A4 (de) Monoklonaler antikörper und dessen verwendung
BRPI0509495A2 (pt) anticorpo humanizado
EP2143734A4 (de) Funktionelles epitop von osteopontin, monoklonaler antiosteoponinantikörper und verwendung davon
PL1718678T3 (pl) Przeciwciało monoklonalne przeciw ludzkiej tenascynie
FI20020807A0 (fi) Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita
DK1812475T3 (da) Immunglobulinfraktioner
GB0415644D0 (en) Monoclonal antibody
HK1108457A (en) Chimeric and humanised monoclonal antibodies against interleukin-13
ATE506966T1 (de) Humanisierte super-antikörper